Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Hearn J. Cho, M.D., Ph.D.
Chief Medical Officer
Principal Investigator - Madhav V. Dhodapkar, M.D.
Medical Monitor
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University
Atlanta, Georgia, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Washington University School of Medicine Division of Medical Oncology
St Louis, Missouri, United States
- Hackensack Meridian Medical Center
Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Mount Sinai School of Medicine
New York, New York, United States
- Levine Cancer Institute
Charlotte, North Carolina, United States
- Ut Southwestern Medical Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Jul 2020
- Primary completion
- 30 Aug 2024
- Completion
- 30 Aug 2024
- Last update posted
- 14 Feb 2025
- Registered enrollment
- 14
- Registry id
- NCT04150965
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.